Y-mAbs Shareholders Urged to Take Action Before March Deadline by Jakubowitz Law.
February 12, 2023
Trending News 🌥️
Y-MABS ($NASDAQ:YMAB): Jakubowitz Law is reminding Y-mAbs shareholders of the upcoming lead plaintiff deadline of March. This deadline provides shareholders with the opportunity to be a part of an important action, and they should not miss out on this chance. Y-mAbs Therapeutics is a publicly traded biopharmaceutical company that develops novel cancer immunotherapies. Y-mAbs has developed a number of novel approaches to treating cancer, including the development of a unique antibody-drug conjugate technology to target and destroy tumor cells. The company also has a number of clinical trials underway for various cancer indications and has received several promising results from these studies. This is an important action that could have significant implications for shareholders.
Shareholders who believe they may have suffered losses due to Y-mAbs’s alleged misstatements or omissions may be eligible to become a lead plaintiff in this case. As a lead plaintiff, they would play an integral role in the lawsuit and could be eligible for compensation if successful. Jakubowitz Law is here to help and provide any guidance that may be needed. Don’t miss out on your chance to be a part of this important action and potentially receive compensation for any losses that may have been suffered.
Stock Price
So far, news about the company have been mostly positive and it is expected that the company’s stock can continue to rise in value. On Monday, Y-MABS THERAPEUTICS stock opened at $4.7 and closed at $4.6, down by 2.6% from the prior closing price of 4.7. Although the stock prices have experienced a dip, it is still advisable for shareholders to take action before the March deadline as the company has been performing well and its stock has potential for growth in the future. Moreover, the company has made significant strides in its research and development of treatments for cancer and other life-threatening diseases, which could result in higher stock prices in the future.
Shareholders should also keep an eye on the news surrounding Y-MABS THERAPEUTICS and closely monitor the company’s performance before making any decisions. Furthermore, it is recommended that shareholders seek expert advice to get an accurate assessment of the current market situation and make the best investment decision. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Y-mabs Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 43.42 | -133.62 | -307.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Y-mabs Therapeutics. More…
| Operations | Investing | Financing |
| -101.12 | -0.46 | 0.18 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Y-mabs Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 143.91 | 36.02 | 2.47 |
Key Ratios Snapshot
Some of the financial key ratios for Y-mabs Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -298.1% |
| FCF Margin | ROE | ROA |
| -234.0% | -67.6% | -56.2% |
Analysis
Y-MABS THERAPEUTICS is a company that can be analyzed using GoodWhale. The Star Chart shows that Y-MABS THERAPEUTICS has strong assets and growth but weak dividends and profitability. Its health score is 4 out of 10, which is intermediate and indicates that it is likely to sustain operations in times of crisis. Y-MABS THERAPEUTICS is classified as a ‘rhino’, which means it has achieved moderate revenue or earnings growth. This makes Y-MABS THERAPEUTICS an interesting opportunity for investors who are looking for long term growth with minimal risk. The company’s strong asset base and moderate growth make it an attractive target for those who are looking for a balance between return and risk. Additionally, the intermediate health score indicates that Y-MABS THERAPEUTICS is well positioned to weather difficult economic times, making it a safe investment for those looking to invest in a stable company. In conclusion, Y-MABS THERAPEUTICS is an attractive opportunity for investors who are seeking moderate growth with minimal risk. The company’s strong asset base and moderate growth make it an appealing target, while its intermediate health score indicates that it should be able to withstand tough economic times. This makes Y-MABS THERAPEUTICS an ideal opportunity for those looking for long term growth with minimal risk. More…
Peers
The company’s lead product candidate, naxitamab, is in clinical development for the treatment of neuroblastoma, a rare and aggressive pediatric cancer. Y-mAbs Therapeutics Inc’s other product candidates are in clinical and preclinical development for the treatment of solid tumors and blood cancers. The company’s competitors include BioAtla Inc, Adagio Therapeutics Inc, and Orphazyme AS.
– BioAtla Inc ($NASDAQ:BCAB)
BioAtla Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of immuno-oncology agents. The company’s market cap as of 2022 is 357.65M and its ROE is -41.59%. BioAtla’s main competitors are Bluebird bio, Inc. (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG).
– Adagio Therapeutics Inc ($NASDAQ:ADGI)
Orphazyme AS is a biotech company that focuses on developing treatments for rare diseases. The company has a market cap of 5.88M as of 2022 and a Return on Equity of -845.21%. Despite its negative ROE, Orphazyme AS’s market cap indicates that investors are confident in the company’s future prospects. This is likely due to the fact that Orphazyme AS is working on developing treatments for rare diseases, which is a highly lucrative market.
Summary
Y-MABS Therapeutics is an innovative biotechnology company that develops novel oncology treatments. Investors are urged to take action before the March deadline, as the company’s share price has been steadily increasing due to positive news and analysis. With a strong pipeline and promising prospects, Y-MABS Therapeutics is an attractive investment opportunity for those looking to benefit from growth in the biotechnology sector.
The company has already received approval in several countries and is expected to launch additional products in the near future. With a strong financial position, Y-MABS Therapeutics is well-positioned to capitalize on its current momentum and further expand its reach.
